GEP100/Arf6 Is Required for Epidermal Growth Factor-Induced ERK/Rac1 Signaling and Cell Migration in Human Hepatoma HepG2 Cells by Hu, ZhenZhen et al.
GEP100/Arf6 Is Required for Epidermal Growth Factor-
Induced ERK/Rac1 Signaling and Cell Migration in
Human Hepatoma HepG2 Cells
ZhenZhen Hu
1,2., Jun Du
3., Ling Yang
4, YiChao Zhu
1, Yu Yang
1, DaTong Zheng
2, Akimasa Someya
5,
Luo Gu
6*, Xiang Lu
7*
1Department of Physiology, Nanjing Medical University, Nanjing, China, 2Department of Pediatrics, The Second Affiliated Hospital of Nanjing Medical University, Nanjing,
China, 3State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China, 4Department of Cardiology, The Third Affiliated Hospital of Suzhou
University, Suzhou, China, 5Department of Host Defense and Biochemical Research, Juntendo University School of Medicine, Tokyo, Japan, 6Cancer Center, Nanjing
Medical University, Nanjing, China, 7Department of Geriatrics, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China
Abstract
Background: Epidermal growth factor (EGF) signaling is implicated in the invasion and metastasis of hepatoma cells.
However, the signaling pathways for EGF-induced motility of hepatoma cells remain undefined.
Methodology/Principal Findings: We found that EGF dose-dependently stimulated the migration of human hepatoma cells
HepG2, with the maximal effect at 10 ng/mL. Additionally, EGF increased Arf6 activity, and ectopic expression of Arf6 T27N,
a dominant negative Arf6 mutant, largely abolish EGF-induced cell migration. Blocking GEP100 with GEP100 siRNA or
GEP100-gPH, a pleckstrin homology (PH) domain deletion mutant of GEP100, blocked EGF-induced Arf6 activity and cell
migration. EGF also increased ERK and Rac1 activity. Ectopic expression GEP100 siRNA, GEP100-gPH, or Arf6-T27N
suppressed EGF-induced ERK and Rac1 activity. Furthermore, blocking ERK signaling with its inhibitor U0126 remarkably
inhibited both EGF-induced Rac1 activation as well as cell migration, and ectopic expression of inactive mutant form of Rac1
(Rac1-T17N) also largely abolished EGF-induced cell migration.
Conclusions/Significance: Taken together, this study highlights the function of the PH domain of GEP100 and its regulated
Arf6/ERK/Rac1 signaling cascade in EGF-induced hepatoma cell migration. These findings could provide a rationale for
designing new therapy based on inhibition of hepatoma metastasis.
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Introduction
Epidermal growth factor (EGF) has a profound effect on the
differentiation of specific cells in vivo, and has been shown to be
a potent mitogenic factor for a variety of cultured cells [1]. It is
noteworthy that EGF produced by tumor-associated macro-
phages also acts as a chemoattractant in promoting motility of
various types of human cancer cells [2,3]. Specific inhibition of
EGF receptors (EGFR) abolishes cytoskeleton remodeling and
migration of cancer cells in response to EGF [4,5]. However, the
molecular mechanisms underlying the effect of EGF/EGFR on
tumor cell migration are not completely understood to date.
EGFR is made up of an extracellular ligand-binding domain,
a short hydrophobic transmembrane domain and a cytoplasmic
tyrosine kinase-containing domain. Binding of ligands to the
extracellular domain of EGFR induces the formation of receptor
homo- or heterodimers, and subsequent activation of the intrinsic
tyrosine kinase domain. These phosphorylated residues serve as
docking sites for proteins containing Src homology 2 (SH2) and
phosphotyrosine binding (PTB) domains, such as Grb2, Crk and
the intercellular kinase Src, and leads to activation of different
signaling molecules that transmit the signal in the cell [6]. Indeed,
activation of EGFR by EGF has been found to induce
tumorigenesis through upregulation of signaling pathways, in-
cluding PI3K/Akt, STAT, Ras/Raf/MAPK [7,8] and members
of Rho GTPase family such as Rac1 [9].
GEP100, one of the guanine nucleotide exchanging factors
(GEFs) for Arf6, has been implicated in EGF signaling and
cancer invasion. GEP100 is expressed in most of primary breast
ductal carcinomas, and is preferentially co-expressed with EGFR
in malignant cases [10]. It has been shown that GEP100
interacts specifically with EGFR and plays a pivotal role in
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on human hepatoma HepG2 cells, GEP100 interacts directly
with a-catenin and regulates actin cytoskeleton remodeling and
cell adhesion [11]. Inhibition of GEP100 by siRNA was also
reported to enhance cell attachment and spreading on fibronec-
tin-coated substrates [12]. GEP100 contains a Sec7 domain, an
incomplete IQ-motif, and a pleckstrin homology (PH) domain.
The PH domain of GEP100 differs greatly from that of other Arf
GEFs in regions involved in phospholipid binding [13]. In fact,
the PH domain of GEP100 was identified to bind directly to
Tyr1068/1086-phosphorylated EGFR and was required for
EGF-stimulated Arf6 activation in MDA-MB-231 breast cancer
cells [14]. Because Arf6 has been identified to play an important
role in cancer cell migration [15] and the PH domain of
GEP100 links EGFR signaling to Arf6 activation, it is worthwhile
to explore whether the PH domain of GEP100 is involved in
EGF-induced Arf6 signaling pathway and cancer cell migration
ability. Arf6 has been identified as a potent modulator of
extracellular-signal-regulated kinase (ERK) and Rac1 activity
[16,17]. Rac1, one of the best-characterized member of small
GTPases family, was reported to be associated with lamellipodial
dynamics and chemotactic migration [18]. Although a cross-talk
between signaling from Arf6, ERK and Rac1 may occur in
different cellular processes, the precise molecular mechanisms
implicating GEP100 in cancer cell motility have not yet been
unraveled. In the present study, we investigated the signaling
mechanisms underlying the effect of GEP100, especially the
function of its PH domain, on hepatoma cell migration. Our
results demonstrate that EGF stimulates hepatoma HepG2 cell
migration through GEP100-dependent activation of the Arf6/
ERK/Rac1 signaling pathway.
Results
EGF Stimulates Migration of HepG2 Cells in vitro
To assess the effect of EGF on cancer cell migration, human
hepatoma HepG2 cells were treated with various concentrations of
EGF, and the migration rate of cells was measured by wound
closure assay as described in ‘‘Materials and Methods’’. Similar to
the findings of Price et al. [19], we found that 5 ng/mL EGF
caused an increase in cell migration over untreated cells. Maximal
increase in cell migration was observed with 10 ng/mL EGF,
which induced an approximately 1.7-fold increase in cell
migration over untreated cells and tapered off with further
increase in the dose of EGF up to 100 ng/mL (Fig. 1A). Cell
migration was also assessed by Transwell migration assays. HepG2
cells were treated with 10 ng/mL EGF, which increased the
number of migrated cells by 5 folds over that of controls (Fig.1B).
To determine whether EGF-induced cell migration was associated
with increased cell proliferation, we treated HepG2 cells with
10 ng/mL EGF for 24 h, and cellular proliferation was examined
by cell cycle analysis. The results revealed that the percentages of
cells in the S and G2 phase were not altered significantly in EGF
treated cells compared to the control cells (Fig. 1C). Our MTT
assays additionally showed that treatment with 10 ng/ml EGF for
24 and 48 h did not noticeably increase the proliferation of
HepG2 cells (Fig. 1D).
GEP100/Arf6 Regulates EGF-induced Cell Migration
in vitro
Accumulating evidence has indicated that Arf6 can be activated
by various stress stimuli such as EGF [20]. We wished to examine
whether Arf6 influenced cell migration in hepatoma cells after
EGF treatment. We first investigated whether EGF could regulate
Arf6 activation. Pulldown assays revealed that EGF induced Arf6
activation (Arf6-GTP) with an early peak at 15 min, which then
returned to the basal levels, while the level of Arf6 protein in
HepG2 cells remained unmodified during 4 h of EGF treatment
(Fig. 2A). To determine whether EGF-induced cell migration was
Arf6-dependent, we blocked Arf6 activity by transfecting these
cells with Arf6 T27N (dominant negative mutant) (Fig. S1), and
examined cell migration after EGF stimulation. We found that, in
cells transfected with the empty vector, cell migration rate was
increased significantly after the addition of EGF. However, in cells
transfected with the Arf6 T27N expression vector, such stimula-
tory effect of EGF on cell migration was eliminated (Fig. 2B).
These findings indicate that the activation of Arf6 is essential for
EGF-stimulated hepatoma cell migration.
High level of GEP100, one of GEFs for Arf6, was expressed in
HepG2 cells (Fig. S2). To determine whether EGF-stimulated Arf6
activity was GEP100-dependent, we blocked GEP100 expression
by transfecting these cells with GEP100 siRNA (Fig. S3), and then
examined Arf6 activity after EGF stimulation. We found that,
compared with scrambled siRNA (irrelated), siRNA against
GEP100 effectively reduced Arf6 activation in HepG2 cells after
EGF-stimulation (Fig. 2C). Additionally, we examined the function
of PH domain of GEP100 on EGF-induced Arf6 activation. The
results revealed that transfection of GEP100-gPH markedly
decreased Arf6 activation after stimulation with EGF. Expression
levels of empty vector or GEP100-gPH were verified using total
protein from HepG2 cells and immunoblotted using anti-GFP
antibody (Fig. S4).
To further determine whether EGF stimulated cancer cell
migration in a GEP100-dependent manner, we transfected
HepG2 cells with GEP100 siRNA or GEP100-gPH and
examined how these cells responded to EGF by Transwell
migration assays. GEP100 siRNA or the mutant GEP100-gPH
resulted in a remarkable inhibition of EGF-promoted cell
migration (Fig. 2D), suggesting that GEP100, particularly its PH
domain, is required for EGF-induced migration of these cells.
GEP100/Arf6 Regulates ERK Activation during EGF-
induced Cell Migration
To determine whether the regulation of HepG2 cell migration
by GEP100 depended on ERK activation, we investigated the
effect of GEP100/Arf6 on ERK activation using immunoblotting
assays. We found that the level of phospho-ERK was significantly
increased at 15 min after EGF stimulation, whereas the total
protein level of ERK remained unaltered (Fig. 3A). The results
showed that both GEP100 siRNA and GEP100-gPH largely
inhibited EGF-induced ERK activity (Fig. 3B). ERK activity was
also markedly inhibited by Arf6-T27N transfection (Fig. 3C).
These results suggest that GEP100/Arf6 acts as an upstream
effector of ERK activation.
The effect of ERK inhibitor on cell migration was also
investigated.Pretreatmentwith10 mMU0126resultedinaremark-
able inhibition of EGF-promoted cell migration (Fig. 3D). These
results suggest that ERK acts as a downstream effector of GEP100
and Arf6 in mediating EGF-stimulated hepatoma cell migration.
GEP100/Arf6 Regulates Rac1 Activation during EGF-
induced Cell Migration
Accumulating evidence has indicated that Rac1 is a downstream
effector of Arf6 in normal cells [21,22], to determine whether Rac1
was the downstream target of GEP100/Arf6 activation by EGF in
our system, we examined endogenous Rac1 activation after EGF
treatment by immunoblotting assays. The results revealed a time-
GEP100/Arf6/ERK/Rac1 Pathway in Cell Migration
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activation was significantly induced from 5 to 240 min after EGF
stimulationwithapeakat30 min(Fig.4A).WetransfectedGEP100
siRNA or overexpressed GEP100-gPH or Arf6-T27N in cells and
then examined Rac1 activity after EGF stimulation. The results
showedthatRac1activationwaslargelyabolishedincellsexpressing
GEP100 siRNA, GEP100-gPH and Arf6-T27N, respectively,
indicating that the GEP100/Arf6 signaling pathway is essential for
EGF-stimulated Rac1 activation (Fig. 4B, 4C).
To investigate whether Rac1 activation was required for EGF-
stimulated migratory effects, we blocked Rac1 activation by
transfecting cells with a domain negative mutant of Rac1-T17N.
The results showed that cells with Rac1-T17N prior to EGF
treatment significantly suppressed cell migration (Fig. 4D), suggest-
ing that activation of Rac1 downstream of GEP100/Arf6 is
necessary for EGF-stimulated cell migration. Expression levels of
empty vector and Rac1-T17N were verified using total protein
from cells and immunoblotted using anti-GFP antibody (Fig. S5).
Cell motility requires extensions of the plasma membrane
driven by reorganization of the actin cytoskeleton [23], so we
performed fluorescent phalloidin staining to investigate the
distribution pattern of F-actin in HepG2 cells. The results revealed
that GEP100-gPH inhibited the formation of membrane ruffles
induced by EGF (Fig. 4E). Thus, the findings from the cell
biological assay are consistent with the biochemical evidence that
GEP100 activation is required for cell motility.
Inhibition of ERK Activity Suppresses GEP100/Arf6-
mediated Rac1 Activation
ERK has been implicated in the Rac1 signaling pathway in
various human cancer cell lines [24,25,26]. Therefore, we assessed
Figure 1. Effect of EGF on migration of HepG2 cells. (A) Relative cell migration rate was determined using wound closure assay in HepG2 cells
incubated in the absence or presence of 5, 10, 30, 50, and 100 ng/mL EGF for 24 h. (B) The cell migration was assessed by the Transwell migration
assay in HepG2 cells incubated in the absence (control) or presence of 10 ng/mL EGF for 8 h. (C) HepG2 cells were cultured in the absence (control) or
presence of 10 ng/mL EGF for 24 h and cell cycle was analyzed by flow cytometry. (D) HepG2 cells were cultured in the absence (control) or presence
of 10 ng/mL EGF for 24 or 48 h and cell proliferation was analyzed by MTT assays. Each value represents the mean 6 SD of 5 independent
determinations. *: P,0.05, referring to the difference between cells treated with and without EGF.
doi:10.1371/journal.pone.0038777.g001
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by analyzing activation of Rac1. The results showed that Rac1
activation was increased significantly in EGF-treated cells;
however, the increases of these parameters were much less in
the same treated cells pretreated with 10 mM U0126 (Fig. 5A). To
determine whether the regulation between Rac1 and ERK in
these cancer cells was bi-directional, cells transfected with Rac1-
T17N were stimulated with EGF. We found that inhibition of
Rac1 activation did not alter EGF-induced augmentation of ERK
phosphorylation (Fig. 5B). These results suggest that ERK acts as
an upstream molecule of Rac1 signaling.
Figure 2. Effects of GEP100/Arf6 on EGF-induced cell migration. (A) EGF induces activation of Arf6. Serum-starved cell monolayers were
treated with 10 ng/mL EGF for the indicated times. Cellular lysates were assayed for active Arf6 by pulldown assays as described in ‘Materials and
methods’. The data were mean 6 SD of three independent experiments. (B) Effect of the inactive mutant of Arf6 on EGF-stimulated migration. HepG2
cells were transiently transfected with the empty vector pEGFP-N1 and Arf6-T27N, respectively. Cells were then subjected to a Transwell migration
assay in the presence of 10 ng/mL EGF for 8 h. (C) Both GEP100-siRNA and GEP100-gPH transfection inhibit Arf6 activation. Cells transfected with
GEP100-siRNA or GEP100-gPH were stimulated with EGF for 15 min, and Arf6-GTP levels were examined. (D) Effects of the GEP100-siRNA and
GEP100-gPH on EGF-stimulated cell migration. HepG2 cells infected with GEP100-siRNA and GEP100-gPH as indicated were subjected to a Transwell
migration assay in the presence of 10 ng/mL EGF for 8 h. *: P,0.05, referring to the difference between cells treated with and without EGF.
#: P,0.05
(t-test), referring to the difference between the cells transfected with Arf6–T27N or GEP100 siRNA or GEP100-gPH plus EGF and the cells transfected
with scrambled siRNA (irr siRNA) or empty vector plus EGF.
doi:10.1371/journal.pone.0038777.g002
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activation of ERK. HepG2 cells were starved overnight, followed by treatment with 10 ng/mL EGF for the indicated times. Phosphorylation of ERK at
Thr202/Tyr204 was determined as described in ‘Materials and methods’. (B) Both GEP100-siRNA and GEP100-gPH transfection inhibit ERK activation.
Cells transfected with GEP100-siRNA or GEP100-gPH were stimulated with EGF for 15 min, and the activation of ERK was examined. (C) EGF-activated
ERK depends on Arf6. HepG2 cells were transiently transfected with the empty plasmid pEGFP-N1 and Arf6-T27N, respectively. The cells were then
treated with or without EGF (10 ng/mL) for 15 min after an overnight serum starvation and ERK activity was examined. (D) Effect of ERK inhibitor on
EGF-stimulated cell migration. After pretreatment with 10 mM U0126 for 60 min, HepG2 cells were incubated with 10 ng/mL EGF for 8 h and the cell
migration rate was determined by Transwell migration assay. *: P,0.05, referring to the difference between cells treated with and those without EGF.
#: P,0.05 (t-test), referring to the difference between the cells transfected with Arf6–T27N or GEP100 siRNA or GEP100-gPH plus EGF and the cells
transfected with scrambled siRNA (irr siRNA) or empty vector plus EGF.
doi:10.1371/journal.pone.0038777.g003
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activation of Rac1. HepG2 cells were starved overnight, followed by treatment with 10 ng/mL EGF for the indicated times. Rac1 activation was
determined as described in ‘Materials and methods’. (B) Both GEP100-siRNA and GEP100-gPH transfection inhibit Rac1 activation. Cells transfected
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Dysregulation of EGF and its receptors have been proved to
promote tumor growth and metastasis of various types of cancer
[6,27]. In our system, HepG2 cancer cell migration rate was
accelerated after EGF treatment compared with that of the
control, but cell proliferation was not altered. Therefore, EGF
directly activates the migration of hepatoma cells, which is a critical
step for tumor metastasis. Based on this, the signaling mechanisms
underlying the effect of EGF on promoting cancer cell migration
were investigated.
A primary observation in the present study is that both GEP100
siRNA and PH domain deletion mutant GEP100-gPH trans-
fection can significantly inhibit EGF-induced migration as well as
membrane ruffling of HepG2 cells, indicating that GEP100,
especially its PH domain, serves as a key mediator of EGF-
stimulated migration of these cancer cells. It has been shown that
the PH domain of GEP100 is associated with phosphorylated
Tyr951 of VEGFR2 [28], and its PH domain was also reported to
bind to certain phosphorylated tyrosines on EGFR, and mediate
EGF-stimulated breast cancer cell invasion [14]. Similarly, our
results not only showed that GEP100 is necessary for motility of
HepG2 cancer cells in vitro, but also identified the effect of the PH
domain of GEP100 in migration. Following transfection of HepG2
cells with GEP100-gPH plasmids, the migration of these cells was
decreased significantly, showing that deletion of the PH domain of
GEP100 in these cancer cells could impair the migration of these
cancer cells in vitro.
GEP100 signaling is linked to the activation of Arf6 [29,30].
Arf6 belongs to the Ras superfamily of GTP-binding proteins and
its primary role is in membrane trafficking and structural
with GEP100-siRNA or GEP100-gPH were stimulated with EGF for 30 min, and Rac1 activation was examined. (C) EGF-induced activation of Rac1 was
dependent on Arf6. Cells transfected with Arf6-T27N were stimulated with EGF for 30 min, and Rac1 activation was examined. (D) Effect of Rac1-T17N
on EGF-stimulated cell migration. After transfection with the empty vector or Rac1-T17N, HepG2 cells were incubated with 10 ng/mL EGF for 8 h and
the cell migration rate was determined by Transwell migration assay. (E-F) GEP100-gPH blocked EGF-stimulated membrane ruffling. Cells expressing
empty vector or GEP100-gPH were stimulated with EGF for 15 min, fixed and stained for the distribution of actin using TRITC-conjugated phaolloidin
(red). Cells were counterstained with DAPI (blue). Images are representative of at least 3 independent determinations. Magnification,6400. Scale bar,
20 mm. *: P,0.05, referring to the difference between cells treated with and without EGF.
#: P,0.05 (t-test), referring to the difference between cells
transfected with Rac1-T17N, Arf6–T27N or GEP100 siRNA or GEP100-gPH plus EGF and the cells transfected with scrambled siRNA (irr siRNA) or
empty vector plus EGF.
doi:10.1371/journal.pone.0038777.g004
Figure 5. GEP100-dependent Rac1 activation requires ERK activity. (A) EGF-mediated activation of Rac1 requires ERK. HepG2 cells were
treated with 10 mM U0126 for 60 min prior to EGF treatment (10 ng/mL) for 30 min, and then subjected to Rac1 activation analysis. (B) EGF-mediated
ERK activation is Rac1 independent. Cells transfected with Rac1-T17N were stimulated with EGF for 15 min, and then subjected to ERK analysis. *:
P,0.05, referring to the difference between cells treated with and those without EGF.
#: P,0.05 (t-test), referring to the difference between cells
treated with EGF plus U0126 relative to cells treated with EGF alone.
doi:10.1371/journal.pone.0038777.g005
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evidence that Arf6 can be activated by various growth factors, such
as vascular growth factor [32], colony-stimulating factor [33], and
G protein coupled receptor agonists [34]. Our results indicated
that Arf6 plays an essential role in cancer cell migration during
EGF stimulation. Like all GTPases, the Arf6 is under tight spatial
control, which is mediated by guanine nucleotide exchange factors
(GEFs) and GTPase-activating proteins (GAPs) that catalyse GTP
exchange and hydrolysis, respectively. There are 15 genes in
humans encoding proteins bearing the Sec7 domain, a putative
ArfGEF domain [35,36]. Specific GEF allows Arf6 to be activated
in specific signal transduction pathways and coordinate more
elaborate responses to specific demands at localized cellular sites.
Our results indicated that GEP100, the special GEF for Arf6, is
responsible for EGF-induced Arf6 activation in HepG2 cells.
Indeed, we show here that EGF-induced Arf6 activation could be
suppressed by ectopic expression with GEP100 siRNA as well as
GEP100-gPH, so we suggest that the PH domain of GEP100 is
involved in EGF signaling to induce Arf6 activation and migration
of human hepatoma HepG2 cells.
The ability of Arf6 to affect cortical actin cytoskeleton, cell
shape and cell polarity is now well recognized [37]. A recent study
has found that Arf6 is required for EGF-induced glioblastoma cell
proliferation via the activation of PI3K and ERK signaling [38].
ERK has also been implicated in Arf6-mediated epithelial tubule
development in response to hepatocyte growth factor (HGF) [39].
On the other hand, direct evidence that Arf6-GTP leads to Rac1
activation has been obtained [40]. Consistent with these reports,
our results revealed that EGF-induced cell migration was
associated with an increase in ERK and Rac1 activity. Inhibition
of ERK activity by U0126 or suppression of Rac1 activity by
ectopic expression of inactive mutant form of Rac1 (Rac1-T17N)
significantly prevents EGF-induced cell migration, suggesting that
EGF-induced ERK and Rac1 activation was responsible for the
migration of these cancer cells. Furthermore, transfection of
GEP100-gPH, inhibition GEP100 or Arf6 activity by GEP100
siRNA or Arf6 T27N failed to facilitate EGF-induced ERK and
Rac1 activation. Therefore, it may be reasonable to speculate that
EGF-induced ERK and Rac1 activation and cell migration
require the PH domain of GEP100 and are mediated through
the GEP100/Arf6 pathways. It has been reported that the EGFR-
GEP100-Arf6-AMAP1 signaling pathway is specific to breast
cancer invasion and metastasis [41]. Meanwhile, our data
supported the concept that EGF is capable of inducing ERK
and Rac1 activation through the Arf6 pathway, and this process is
associated with hepatoma cell migration where GEP100 was
present.
In some cell types, ERK is a downstream target of the Rac1
signaling cascade, such as in rat basophilic leukemia mast cells,
and inactivation of Rac1 was sufficient to suppress ERK activation
induced by eotaxin [42]. However, in our study, blocking ERK
activity significantly prevents EGF-induced Rac1 activation.
Furthermore, specific downregulation of Rac1 signaling in HepG2
cells did not alter EGF-induced activation of ERK. Our result is
confirmed by a study in intestinal epithelial cells IEC-6, showing
that ERK promoted cell adherens junctions through the activation
of Rac1 [24]. The different results gained by different groups may
be due to the different cell systems used and receptor-coupled
signaling in these studies.
Rac1 is well-known required for the progression and metastasis
of cancer cells by mediating growth factor-induced motility and
invasiveness [43,44]. However, it remains unclear whether
GEP100/Arf6 mediates Rac1 activation through other pathways
in our system. Rac1 is regulated by its GEFs and GAPs. A recent
study showed that the DOCK180/Elmo complex, a Rac1 GEF,
has been responsible for upregulating Rac1 activity and leads to
migration of MDCK cells induced by Arf6 activation [45]. In
addition, Arf6 is also found to form complexes with Rac1 and
IQGAP1 in glioma cells upon HGF stimulation, and IQGAP1 is
essential for Arf6-induced Rac1 activation and cell migration [46].
The role remains to be determined of other signaling molecules
that function downstream of Arf6 in controlling Rac1 activation
and cell migration.
In summary, we presented the first direct evidence that the PH
domain of GEP100 is essential for cancer cell migration in vitro.W e
also identified a signaling pathway implicated in EGF-induced
hepatoma cell migration in which GEP100 was present. EGF
treatment can activate the GEP100-dependent Arf6/ERK/Rac1
cascade in hepatoma cancer cells, which contributes to the
migrative ability of these cells. These findings are of potential
pathophysiological importance for understanding the integration
of migration-related signaling and shed light on new therapeutic
targets for cancer.
Materials and Methods
Cells and Plasmids
Human hepatoma cell line HepG2 was obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and
maintained at 37uC in high glucose Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco,Grand Island, NY) supplemented with
10% fetal bovine serum (FBS) (Hyclone, Logan, UT), 100 units
penicillin/mL, and 100 mg/mL streptomycin in a humidified
atmosphere. Cells were grown on coverslips for fluorescence
staining and on plastic dishes for protein extraction. Cells were
made quiescent by serum starvation overnight followed by drug
treatment.
pEGFP-C2 vector containing dominant negative Rac1-T17N
insert was kindly provided by Dr. Shoshana Ravid (The Hebrew
University, Jerusalem, Israel). Dr. Julie G. Donaldson (Laboratory
of Cell Biology, NIH) generously provided the construct of Arf6-
T27N. Cells were transfected with either pEGFP-C2 or pEGFP-
C2 expressing Rac1-T17N or Arf6-T27N using Lipofectamine
2000 as instructed by the manufacturer (11668, Invitrogen,
Carlsbad, CA, USA). Cells were allowed to grow for 24 to 48 h
post transfection before treatment with EGF where indicated. The
pEGFP-GEP100-WT and pEGFP-GEP100-gPH were kindly
gifted from Dr. Akimasa Someya. Details of plasmids are available
upon request. The sequence of small interfering RNA (siRNA) for
GEP100 was 59-GCGAGAGCUAAAGACCAAUTT-39 and for
the scrambled sequence 59-UUCUCCGAACGUGUCACGUTT-
39 (GenePharma Co.,Shanghai, China). Cells were grown until
approximately 60% confluent and then transfected with GEP100
siRNA or scrambled siRNA using Lipofectamine 2000 as
instructed by the manufacturer.
Wound Closure Assay in vitro
Cells were plated in a 96-well plate. Approximately 48 h later,
when cells were 95,100% confluent, cells were incubated
overnight in DMEM supplemented with 0.1% (w/v) BSA.
Wounding was performed by scraping through the cell monolayer
with a 10-mL pipette tip. Medium and non-adherent cells were
removed, and cells were washed twice with PBS, and new medium
with or without EGF (236-EG, R&D systems, Inc., Minneapolis,
MN, USA) coupled with various inhibitors was added. Cells were
permitted to migrate into the area of clearing for 24 h. Wound
closure was monitored by visual examination under inverted
Nikon TS100 microscope with a 1006objective.
GEP100/Arf6/ERK/Rac1 Pathway in Cell Migration
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HepG2 cells in exponential growth were harvested, washed, and
suspended in DMEM without FBS. Cells (5610
4) were seeded into
polycarbonate membrane inserts (8 mm pore size) in 24-Transwell
cell culture dishes. Cells were allowed to attach to the membrane
for 30 min before the addition of inhibitors. The lower chamber
was filled with 600 mL DMEM without FBS containing 10 ng/mL
EGF as a chemoattractant. Cells were permitted to migrate for
8 h. After the incubation, stationary cells were removed from the
upper surface of the membranes. The cells that had migrated to
the lower surface were fixed and stained with 0.1% crystal violet.
The number of stained cells was counted under an ocular
microscope.
Cell Proliferation Assays
Cells were cultured in the absence or presence of 10 ng/mL
EGF for 24 or 48 h and the proliferation of the cells was analyzed
by staining with propidium iodide and flow cytometry analyses as
described previously [47]. For MTT assay, cells were incubated
with 10 ng/mL EGF for 24 or 48 h, before each time point, 20 mL
MTT solution was added to each well followed by incubation at
37uC for 4 h. After removal of the medium, 150 mL dimethylsulf-
oxide (DMSO) was added to each well. After gentle shaking,
absorbance at 490 nm was measured by using a plate reader
(ELx800, BioTek Instruments, Inc., Vermont, USA). The OD
difference between cells treated with or without EGF was
calculated as relative content (% of control) and expressed
graphically.
Immunoblotting Analysis
Cellular lysates and immunoblotting were performed as pre-
viously depicted [48]. The following antibodies were used: rabbit
anti-GEP100 (G4798, Sigma, St. Louis, MO, USA), mouse anti-
Arf6 (sc-7971, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
mouse anti-Rac1 (05-389, Millipore, Billerica, MA, USA), rabbit
anti-ERK1/2 and anti-phospho-ERK1/2 (Thr202/Tyr204)
(4695,4377,Cell Signaling Technology, Boston, MA, USA), and
mouse anti-GAPDH antibody (MAB374,Chemicon, Temecula,
CA, USA). Digital images of the immunoblots were obtained with
a Chemidoc XRS and analyzed using the image analysis program
Quantity One (Bio-Rad, Hercules, CA, USA).
Actin Cytoskeleton Staining and Immunofluorescence
Cells were fixed in 3.7% paraformaldehyde in PBS for 20 min,
permeabilized in 0.2% Triton X-100 and blocked in PBS
containing 1% BSA for 1 h at room temperature. The cells were
incubated with mouse anti-GFP antibody (sc-53882, Santa Cruz)
for 2 h followed by incubation with FITC-conjugated anti-mouse
antibody for 1 h at room temperature within a moist chamber. F-
actin was stained with TRITC-labeled phalloidin (5 mg/mL)
(P1951, Sigma) for 40 min at room temperature. Following wash
with PBS, the coverslips were mounted on glass slides with DAPI
Fluoromount G (0100-20, Southern Biotech, Birmingham, AL).
Images were collected using a fluorescent microscope (Lecia
DM2500, Wetzlar, Germany). The filter cubes L5 (Excitation
480 nm, Emission 527 nm, Dichroic 505 nm) and TX2 (Excita-
tion 560 nm, Emission 645 nm, Dichroic 595 nm) were used for
GFP and F-actin observation, respectively.
Pulldown Assays
Rac1 and Arf6 activity were measured as previously depicted
[45,49]. In brief,?equal volumes of total cellular protein were
incubated with GST-RBD for detection of active Rac1, or GST-
GGA3 for detection of active Arf6 (gifts from James E Casanova,
University of Virginia, VA) beads captured on MagneGST
Glutathione Particles (Promega, Madison, WI) for 1 h at 4 uC.
The particles were then washed three times with washing buffer
containing 4.2 mM Na2HPO4, 2 mM KH2PO4, 280 mM NaCl,
and 10 mM KCl (pH 7.2), resuspended in 26SDS sample buffer
and subjected to immunoblotting analysis by using a mouse anti-
Rac1 antibody (Upstate Biotechnology, Lake Placid, NY) or
a mouse anti-Arf6 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA).
Statistical Analysis
Statistical analysis was carried out using the SPSS software.
Student’s t test was used to analyze the differences between two
groups. When comparisons between multiple groups were carried
out, one-way ANOVA followed by SNK tests were employed.
Statistical significance was considered at P,0.05.
Supporting Information
Figure S1 Expression of Arf6-T27N in HepG2 cells.
Expression levels of empty vector and Arf6-T27N were verified
using total protein from cells and immunoblotted using anti-GFP
antibody.
(TIF)
Figure S2 Protein levels of GEP100 in HepG2 cells. The
level of GEP100 expression in HepG2 cells was determined as
described in ‘Materials and methods’. MCF-7 cells were used as
negative control. MDA-MB-231 cells were used as positive
control.
(TIF)
Figure S3 The effect of siRNA on the intracellular levels
of GEP100. Total protein extracts from HepG2 cells transfected
with siRNA-GEP100 or scrambled siRNA (mock) were analyzed
by Western blotting for GEP100. GAPDH was used as loading
control.
(TIF)
Figure S4 Expression of GEP100-gPH in HepG2 cells.
Expression levels of empty vector and GEP100-gPH were verified
using total protein from cells and immunoblotted using anti-GFP
antibody.
(TIF)
Figure S5 Expression of Rac1-T17N in HepG2 cells.
Expression levels of empty vector and Rac1-T17N were verified
using total protein from cells and immunoblotted using anti-GFP
antibody.
(TIF)
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